RecruitingNCT06206369

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression


Sponsor

Amsterdam UMC, location VUmc

Enrollment

11,000 participants

Start Date

Oct 31, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).


Eligibility

Min Age: 40 YearsMax Age: 90 Years

Inclusion Criteria2

  • Males and females, 40-90 years old, with an AAA \>3cm. This includes patients with infrarenal, juxtarenal, suprarenal, iliac (defined as 1.5x its normal diameter) aneurysms, as well as mycotic aneurysms. Patients that have had interventions or ruptures will also be included
  • Males and females, 40-90 years old, all PAD patients (Fontaine stages 1,2,3, and 4).

Exclusion Criteria1

  • Patients with an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.

Interventions

OTHERNo intervention, retrospective study

No intervention, retrospective study


Locations(6)

Hospital District of Helsinki and Uusimaa (HUS)

Helsinki, Finland

Asklepios kliniken hamburg

Hamburg, Germany

Amsterdam UMC

Amsterdam, Netherlands

University Hospital Center of São João

Porto, Portugal

University Clinical Centre of Serbia

Belgrade, Serbia

Oxford University Hospitals

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06206369


Related Trials